Results: MTX vs. PBO ✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001) ✅HR for kidney AE on safety labs: 0.73 (0.59-0.91) ✔️HR for kidney AE clinical events: 0.87 (0.56-1.36) ✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)

🤜MTX safe from kidney perspective if baseline CrCl 40+ 🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks

How does MTX affect kidney function/adverse events? Pre-specified analysis of DBRCT: MTX 15-20mg/wk (n=2391) vs. PBO (n=2395) both with folic acid over median f/u 23 months ✅We demonstrated kidney safety of MTX ⚡️⚡️Also a *suggestion* of LESS decline in eGFR for MTX than PBO https://t.co/SZXloLRmnj

• https://twitter.com/jeffsparks/status/1400758056401747971

PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy? ⭐️Mean C3 ⬆️28% compared to 1st trimester ⭐️Mean C4 ⬆️ 11% compared to 1st trimester @RheumNow

#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel ⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls ⭐️RTX lowest seropos of 39%, related to time of infusion ⭐️⬇️ with GC, ABA, MMF ⭐️ MTX not seen to significantly ⬇️ @RheumNow @rheum_covid

#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge

A single dose of LORECIVIVINT IA (Wnt pathway modulator) in Phase 3 study in knee OA: mild improvement of WOMAC pain -8.16[-15.60, -0.71] P=0.032 and function -9.47[-17.09, -1.84] P=0.015 at 6 and 12months with no particular safety signal. #POS0278 #EULAR2021 @RheumNow https://t.co/5qQE6MPjnU

Poster #POS1031 pooled VOYAGE 1&2 and DISCOVER 1&2, GI-related SAE rates low. No uveitis, opportunistic infections, or new onset/exacerbation of IBD in GUS-treated pts. No new safety concerns were identified through 1-year follow up. #EULAR2021 @RheumNow https://t.co/7NxeOu6FLW

• http://ow.ly/zwsd50F3v4n

PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi

• http://ow.ly/Q4wp50F3uTN

JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal. #LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

• https://bit.ly/3fS5SJX

KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal. #OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz

COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI. #OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM

Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD